Background: Pediatric papilledema is a common reason for ophthalmology evaluation in high acuity emergency department and inpatient settings. This study describes the frequency of consultation, causative diagnoses, and presenting characteristics of papilledema at a tertiary care children's hospital.
Methods: All consecutive patients seen in pediatric ophthalmology consultation or diagnosed with papilledema at a large children's hospital between January 1, 2021, and August 18, 2023, were retrospectively reviewed.
Lancet Gastroenterol Hepatol
February 2025
The primary curative therapies for hepatocellular carcinoma are resection or liver transplantation. For patients requiring downstaging or who are unresectable at presentation, the landscape of local treatment options has vastly changed over the past decades. This change is partly due to the paucity of high-level evidence to guide the selection of liver-directed therapies, where physician preference and treatment patterns have historically resulted in relegating external-beam radiation therapy (EBRT) to a secondary option in the treatment of hepatocellular carcinoma in cases where arterially directed therapies or thermal ablations were not possible.
View Article and Find Full Text PDFPurpose: Fear of missing neurologic disorders or visual loss from unrecognized papilledema often leads to emergency department (ED) visits for "papilledema" rule-out/workup. In 2022, our institution initiated an ED "papilledema protocol," a systematic evaluation with a median duration of 28 hours (IQR, 21-34). In 2023, we implemented a hybrid true color non-mydriatic fundus photography (NMFP) and optical coherence tomography (OCT) camera (NMFP/OCT) in our ED with the goal of facilitating ED patient evaluations.
View Article and Find Full Text PDFBackground: External-beam radiation (EBRT) is a noninvasive therapeutic alternative to transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). The objective of this study was to conduct a systematic review and meta-analysis of prospective randomized clinical trials to assess the clinical efficacy of EBRT versus TACE for HCC as either a definitive monotherapy or as a bridge to transplantation/surgery.
Methods: A systematic review and meta-analysis were performed to include prospective randomized trials comparing EBRT versus TACE.